PROMETHEUS Anser VDZ Test Validated For Use in Inflammatory Bowel Disease...
SAN DIEGO Calif. Oct. 12 2016 PRNewswire Prometheus Laboratories Inc. announced today the successful completion of the validation of the new PROMETHEUS Anser VDZ test for use in adult patients treated...
View ArticleFoodpoisoning bacteria may be behind Crohns disease
HAMILTON ON People who retain a particular bacterium in their gut after a bout of food poisoning may be at an increased risk of developing Crohns disease later in life according to a new study led by...
View ArticleInstavit Oral Spray Supplements Now Available at Meijer Stores Throughout...
LOS ANGELES Oct. 12 2016 PRNewswire Putting an end to hardtoswallow pills and high calorie energy drinks Instavit introduces its sophisticated line of oral spray supplements to the Midwest market. The...
View ArticleSoligenix Announces Poster Presentations from its Gastrointestinal Acute...
PRINCETON N.J. Oct. 13 2016 PRNewswire Soligenix Inc. OTCQB SNGXD Soligenix or the Company a latestage biopharmaceutical company focused on developing and commercializing products to treat rare...
View ArticleAllergan Partners with SonarMDÂ to Develop Innovative IBSD Patient Engagement...
DUBLIN Oct. 13 2016 PRNewswire Allergan plc NYSE AGN announced today a collaboration with SonarMDÂ a leader in population health management on the development of clinical decision support CDS and...
View ArticleQu Biologics Publishes Promising Paper on Novel Treatment for Allergic Airway...
VANCOUVER BRITISH COLUMBIA Marketwired 101316 Qu Biologics Inc. a biopharmaceutical company developing Site Specific Immunomodulators SSIs that aim to "reboot" the body's innate immune system announces...
View ArticleExperiment in monkeys raises hopes of "functional cure" for HIV
Treatment hits same target as Takeda's Crohn's diseasedrug
View ArticleT Cell Traffic Stop Halts SIV
An antibody used to treat Crohn’s disease controls simian immunodeficiency virus infection in Rhesus macaques by blocking T cell migration to the gut.
View ArticleA drug used to treat Crohns disease could suppress HIV monkey study suggests
Monkeys infected with SIV who were treated with the drug saw viral loads drop to nearly undetectable levels even after antiretroviral therapy stopped.
View ArticleProtagonist Therapeutics to Present Phase 1 Clinical and Preclinical Data on...
MILPITAS Calif. Oct. 13 2016 PRNewswire Protagonist Therapeutics Inc. NASDAQ PTGX today announced that the company will present two posters detailing clinical data from a Phase 1 clinical trial of...
View ArticleResearchers find 2 distinct genetic subtypes in Crohn's disease patients
University of North Carolina Health Care Crohn's disease a common inflammatory disorder of the intestinal tract can have devastating consequences and is notoriously hard to treat successfully in part...
View ArticleMedical News Today Crohn's disease Discovery of two subtypes could lead to...
Two subtypes of Crohn's colonlike and ileumlike have been discovered in colon tissue samples which could translate to new therapeutic strategies.
View ArticleStudy Identifies Genetic Subtypes of Crohn's Disease
FRIDAY Oct. 14 2016 Crohn's disease appears to have at least two distinct genetic subtypes which could explain why the condition is so hard to treat a new study suggests."The onetreatmentfitsall...
View ArticleResearchers find two distinct genetic subtypes in Crohn's disease patients
Crohn's disease a common inflammatory disorder of the intestinal tract can have devastating consequences for a patient's quality of life and is notoriously hard to treat successfully in part because...
View ArticleCrohn's disease appears to have two distinct genetic subtypes study finds
Crohn's disease a common inflammatory disorder of the intestinal tract can have devastating consequences for a patient's quality of life and is notoriously hard to treat successfully in part because...
View ArticleTwo distinct genetic subtypes found in Crohn's disease patients
Crohn's disease can have devastating consequences and is notoriously hard to treat. Now scientists have made a discovery that could explain why Crohn's is so variable the disease has at least two...
View ArticleBBCIC Announces Major Milestone; Prepares for Comparative Effectiveness and...
ALEXANDRIA Va. Oct. 14 2016 PRNewswireUSNewswire The Biologics & Biosimilars Collective Intelligence Consortium BBCIC this month reached a significant new phase of operation posting research...
View ArticleCelgene reports positive data from Phase Ib study of GED0301 for Crohns disease
USbased Celgene's Swiss subsidiary Celgene International has reported positive data from its exploratory Phase Ib CD001 study of GED0301 mongersen to treat active Crohns disease.
View ArticleGenerics Expand into GI Markets Spurring Growth Reports BCC Research
WELLESLEY MAMarketwired October 17 2016 The generic versions of various expiring blockbuster drugs are keying growth in the gastrointestinal therapeutics and diagnostic markets. BCC Research reveals in...
View ArticleOral GED0301 Phase 1b Results Show Clinical Remission and Endoscopic Response...
Clinical improvement observed early with highest clinical response and remission rates in the 12week treatment group Endoscopic improvement seen across all treatment groups at 12 weeks Safety and...
View Article